0.4856  0.065 (15.51%)		07-16 16:00
Open: 0.43 High: 0.5099 Volume: 2,221,952		Pre. Close: 0.4204 Low: 0.4152 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	0.58	1-year :	0.68
Resists	First :	0.5	Second :	0.58
Pivot price	0.34
Supports	First :	0.37	Second :	0.3
MAs	MA(5) :	0.39	MA(20) :	0.34
	MA(100) :	0.47	MA(250) :	0.57
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	87.2	D(3) :	74.9
RSI	RSI(14): 69.4
52-week	High :	1.24	Low :	0.3

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OSRH ] has closed Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.5 - 0.51	0.51 - 0.51
Low:	0.41 - 0.41	0.41 - 0.41
Close:	0.48 - 0.49	0.49 - 0.49

OSR Holdings, Inc. operates as a Special Purpose Acquisition Company (SPAC) – essentially a blank check entity. Its primary objective is to execute a substantial business combination, which may take the form of a merger, a capital stock exchange, an asset acquisition, a stock purchase, a reorganization, or other comparable strategic transaction with one or more established businesses. The company was incorporated on February 25, 2020, and maintains its principal office in Bellevue, Washington.

Mon, 13 Jul 2026
Hold OSR Health for a year, hit $5 share price, get 6x your original position - Stock Titan

Thu, 02 Jul 2026
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target - Newswire.com

Mon, 22 Jun 2026
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do - News-Press NOW

Thu, 11 Jun 2026
OSR Holdings (OSRH) delays 2026 annual stockholder meeting, new date pending - Stock Titan

Tue, 05 May 2026
After an $815M cancer-drug deal, OSR Holdings gets a new $10 target - Stock Titan

Wed, 29 Apr 2026
OSR Holdings Announces $815M License Agreement for VXM01 - ACCESS Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	35 (M)
Shares Float	15 (M)
Held by Insiders	48.9 (%)
Held by Institutions	0.8 (%)
Shares Short	1,420 (K)
Shares Short P.Month	1,180 (K)

EPS	0.02
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.11
Profit Margin	0 %
Operating Margin	-757.6 %
Return on Assets (ttm)	-6.9 %
Return on Equity (ttm)	-14.8 %
Qtrly Rev. Growth	-36.5 %
Gross Profit (p.s.)	0.01
Sales Per Share	0.07
EBITDA (p.s.)	-0.28
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	1 (M)

PE Ratio	16.18
PEG Ratio	0
Price to Book value	0.15
Price to Sales	6.48
Price to Cash Flow	-3.24

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.